March 22, 2018 / 12:22 PM / 5 months ago

BUZZ-Cardiome Pharma: Canadian regulator accepts drug for review

** U.S.-listed shares of Canadian drugmaker up 14.1 pct at $2.11 premarket

** Health Canada accepts co’s bacterial infection treatment Xydalba for regulatory review two days after Cipher Pharma agrees to buy its Canadian business

** Under deal, Cipher to sublicense commercial rights to Xydalba

** Drug has been available in U.S. since 2014 under trade name Dalvance

** Cardiome expects review decision in Q3 2018

** Up to Wednesday’s close, stock had fallen ~40 pct over the past year (Reporting by Tamara Mathias in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below